Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10641791 | 0.84 | LPL (0.49) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL5543430 | 0.83 | LPL (0.47) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL11871771 | 0.82 | LPL (0.56) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL29767685 | 0.82 | LPL (0.56) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL9418466 | 0.82 | LPL (0.56) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL5253068 | 0.79 | S1PR1 (0.54) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL11855197 | 0.79 | LPL (0.57) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL22547606 | 0.79 | LPL (0.57) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL6627133 | 0.79 | LPL (0.53) | LPLLIPGS1PR1S1PR4S1PR5 | |
| SCHEMBL11677098 | 0.79 | LPL (0.53) | LPLLIPGS1PR1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286353-A1 | ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF | FUJIFILM CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100240908-A1 | ACETYLENE COMPOUND | FUJIFILM CORPORATION (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2202221-A1 | ACETYLENE COMPOUND | Fujifilm Corporation (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240908-A1 | ACETYLENE COMPOUND | NAT1, KATNA1, KAT2B | LPL 4749/4885LIPG 4862/4885S1PR1 4414/4885 |
| US-20100286353-A1 | ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF | KAT8, HDAC10, SSRP1 | LPL 4605/4885LIPG 4583/4885S1PR1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.